Case report: Responses to the combination of gemcitabine with sirolimus in two patients with TSC-mutated sarcomas

TSC-mutated sarcomas are rare molecular and histologic types of sarcoma. Due to the presence of their specific oncogenic driver mutation, these sarcomas are particularly sensitive to mTOR inhibitors. Recently, nab-sirolimus, an albumin-bound mTOR inhibitor, was approved by the Food and Drug Administ...

Descripción completa

Detalles Bibliográficos
Autores principales: Nassif, Elise F., Joseph, Cissimol P., Lazcano, Rossana, Joseph, Jocelyn T., Thirasastr, Prapassorn, Lazar, Alexander J., Somaiah, Neeta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947835/
https://www.ncbi.nlm.nih.gov/pubmed/36845725
http://dx.doi.org/10.3389/fonc.2023.1046442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947835/
https://www.ncbi.nlm.nih.gov/pubmed/36845725
http://dx.doi.org/10.3389/fonc.2023.1046442

Ejemplares similares